Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$73.61
-2.72-3.56%
At close: -
$73.61
0.000.00%
After Hours: 4:02 PM EDT
Comments
Loading...
Sarepta Therapeutics Analyst Ratings and Price Targets | NASDAQ:SRPT | Benzinga
Sarepta Therapeutics Inc has a consensus price target of $164.2 based on the ratings of 25 analysts. The high is $230 issued by Leerink Partners on June 24, 2024. The low is $75 issued by HC Wainwright & Co. on March 19, 2025. The 3 most-recent analyst ratings were released by Scotiabank, Cantor Fitzgerald, and HC Wainwright & Co. on March 20, 2025, March 19, 2025, and March 19, 2025, respectively. With an average price target of $106 between Scotiabank, Cantor Fitzgerald, and HC Wainwright & Co., there's an implied 44.00% upside for Sarepta Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Scotiabank
Cantor Fitzgerald
HC Wainwright & Co.
Deutsche Bank
Needham
1calculated from analyst ratings
Analyst Ratings for Sarepta Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/20/2025 | Buy Now | 8.68% | Scotiabank | Louise Chen58% | $105 → $80 | Maintains | Sector Perform | Get Alert |
| 03/19/2025 | Buy Now | 121.44% | Cantor Fitzgerald | Kristen Kluska70% | $163 → $163 | Reiterates | Overweight → Overweight | Get Alert |
| 03/19/2025 | Buy Now | 1.89% | HC Wainwright & Co. | Mitchell Kapoor44% | $75 → $75 | Reiterates | Sell → Sell | Get Alert |
| 03/19/2025 | Buy Now | 34.49% | Deutsche Bank | David Hoang42% | $124 → $99 | Maintains | Hold | Get Alert |
| 03/18/2025 | Buy Now | 174.42% | Needham | Gil Blum51% | $202 → $202 | Reiterates | Buy → Buy | Get Alert |
| 03/18/2025 | Buy Now | 121.44% | Cantor Fitzgerald | Kristen Kluska70% | $163 → $163 | Reiterates | Overweight → Overweight | Get Alert |
| 03/07/2025 | Buy Now | 42.64% | Scotiabank | Louise Chen58% | → $105 | Initiates | → Sector Perform | Get Alert |
| 02/27/2025 | Buy Now | 118.72% | RBC Capital | Brian Abrahams52% | $165 → $161 | Maintains | Outperform | Get Alert |
| 02/27/2025 | Buy Now | 174.42% | Needham | Gil Blum51% | $202 → $202 | Reiterates | Buy → Buy | Get Alert |
| 02/27/2025 | Buy Now | 1.89% | HC Wainwright & Co. | Mitchell Kapoor44% | $75 → $75 | Reiterates | Sell → Sell | Get Alert |
| 02/13/2025 | Buy Now | 1.89% | HC Wainwright & Co. | Mitchell Kapoor44% | $75 → $75 | Reiterates | Sell → Sell | Get Alert |
| 01/30/2025 | Buy Now | 1.89% | HC Wainwright & Co. | Raghuram Selvaraju43% | $75 → $75 | Reiterates | Sell → Sell | Get Alert |
| 01/27/2025 | Buy Now | 174.42% | Needham | Gil Blum51% | $202 → $202 | Reiterates | Buy → Buy | Get Alert |
| 01/15/2025 | Buy Now | 1.89% | HC Wainwright & Co. | Mitchell Kapoor44% | $75 → $75 | Reiterates | Sell → Sell | Get Alert |
| 01/14/2025 | Buy Now | 174.42% | Needham | Gil Blum51% | $202 → $202 | Reiterates | Buy → Buy | Get Alert |
| 12/19/2024 | Buy Now | 1.89% | HC Wainwright & Co. | Mitchell Kapoor44% | $75 → $75 | Reiterates | Sell → Sell | Get Alert |
| 12/03/2024 | Buy Now | 1.89% | HC Wainwright & Co. | Mitchell Kapoor44% | $80 → $75 | Maintains | Sell | Get Alert |
| 11/27/2024 | Buy Now | 147.25% | Piper Sandler | Biren Amin40% | $200 → $182 | Maintains | Overweight | Get Alert |
| 11/27/2024 | Buy Now | 174.42% | Needham | Gil Blum51% | $205 → $202 | Maintains | Buy | Get Alert |
| 11/25/2024 | Buy Now | 8.68% | HC Wainwright & Co. | Mitchell Kapoor44% | → $80 | Initiates | → Sell | Get Alert |
| 11/07/2024 | Buy Now | 103.78% | Guggenheim | Whitney Ijem46% | $148 → $150 | Maintains | Buy | Get Alert |
| 11/07/2024 | Buy Now | 162.19% | Baird | Brian Skorney57% | $200 → $193 | Maintains | Outperform | Get Alert |
| 11/07/2024 | Buy Now | 126.87% | Cantor Fitzgerald | Kristen Kluska70% | $152 → $167 | Upgrade | Neutral → Overweight | Get Alert |
| 11/07/2024 | Buy Now | 130.95% | Evercore ISI Group | Gavin Clark-Gartner41% | $179 → $170 | Maintains | Outperform | Get Alert |
| 11/07/2024 | Buy Now | 178.49% | Needham | Gil Blum51% | $205 → $205 | Reiterates | Buy → Buy | Get Alert |
| 10/21/2024 | Buy Now | 147.25% | RBC Capital | Brian Abrahams52% | $182 → $182 | Reiterates | Outperform → Outperform | Get Alert |
| 10/21/2024 | Buy Now | 124.15% | Jefferies | Andrew Tsai29% | → $165 | Initiates | → Buy | Get Alert |
| 10/14/2024 | Buy Now | 178.49% | Needham | Gil Blum51% | $205 → $205 | Reiterates | Buy → Buy | Get Alert |
| 10/10/2024 | Buy Now | 103.78% | Raymond James | Danielle Brill43% | → $150 | Reinstates | → Outperform | Get Alert |
| 10/04/2024 | Buy Now | 147.25% | RBC Capital | Brian Abrahams52% | $181 → $182 | Maintains | Outperform | Get Alert |
| 09/20/2024 | Buy Now | 106.49% | Cantor Fitzgerald | Kristen Kluska70% | $152 → $152 | Reiterates | Neutral → Neutral | Get Alert |
| 09/19/2024 | Buy Now | 145.89% | RBC Capital | Brian Abrahams52% | $181 → $181 | Reiterates | Outperform → Outperform | Get Alert |
| 09/06/2024 | Buy Now | 145.89% | RBC Capital | Brian Abrahams52% | $181 → $181 | Reiterates | Outperform → Outperform | Get Alert |
| 08/15/2024 | Buy Now | 145.89% | RBC Capital | Brian Abrahams52% | $181 → $181 | Reiterates | Outperform → Outperform | Get Alert |
| 08/08/2024 | Buy Now | 145.89% | RBC Capital | Brian Abrahams52% | $182 → $181 | Maintains | Outperform | Get Alert |
| 08/08/2024 | Buy Now | 117.36% | Citigroup | David Hoang42% | $176 → $160 | Maintains | Neutral | Get Alert |
| 08/08/2024 | Buy Now | 106.49% | Cantor Fitzgerald | Kristen Kluska70% | $167 → $152 | Maintains | Neutral | Get Alert |
| 08/08/2024 | Buy Now | 171.7% | Piper Sandler | Biren Amin40% | $205 → $200 | Maintains | Overweight | Get Alert |
| 08/08/2024 | Buy Now | 143.17% | Evercore ISI Group | Gavin Clark-Gartner41% | $185 → $179 | Upgrade | In-Line → Outperform | Get Alert |
| 08/08/2024 | Buy Now | 175.78% | Barclays | Gena Wang51% | $226 → $203 | Maintains | Overweight | Get Alert |
| 07/29/2024 | Buy Now | 147.25% | RBC Capital | Brian Abrahams52% | → $182 | Upgrade | Sector Perform → Outperform | Get Alert |
| 07/01/2024 | Buy Now | 178.49% | Piper Sandler | Biren Amin40% | $205 → $205 | Maintains | Overweight | Get Alert |
| 06/27/2024 | Buy Now | 219.25% | Needham | Gil Blum51% | $235 → $235 | Reiterates | Buy → Buy | Get Alert |
| 06/26/2024 | Buy Now | 139.1% | Citigroup | David Hoang42% | $172 → $176 | Downgrade | Buy → Neutral | Get Alert |
| 06/24/2024 | Buy Now | 171.7% | Morgan Stanley | Matthew Harrison60% | $165 → $200 | Maintains | Overweight | Get Alert |
| 06/24/2024 | Buy Now | 151.32% | Evercore ISI Group | Gavin Clark-Gartner41% | $139 → $185 | Maintains | In-Line | Get Alert |
| 06/24/2024 | Buy Now | 171.7% | BMO Capital | Kostas Biliouris34% | $170 → $200 | Maintains | Outperform | Get Alert |
| 06/24/2024 | Buy Now | 212.46% | Leerink Partners | Mani Foroohar45% | $165 → $230 | Maintains | Outperform | Get Alert |
| 06/21/2024 | Buy Now | 124.15% | Morgan Stanley | Matthew Harrison60% | $165 → $165 | Reiterates | Overweight → Overweight | Get Alert |
| 06/21/2024 | Buy Now | 113.29% | Piper Sandler | Biren Amin40% | $157 → $157 | Maintains | Overweight | Get Alert |
| 06/21/2024 | Buy Now | 73.89% | Cantor Fitzgerald | Kristen Kluska70% | $128 → $128 | Reiterates | Neutral → Neutral | Get Alert |
| 06/21/2024 | Buy Now | 147.25% | RBC Capital | Brian Abrahams52% | $142 → $182 | Maintains | Sector Perform | Get Alert |
| 06/21/2024 | Buy Now | 207.02% | Barclays | Gena Wang51% | $185 → $226 | Maintains | Overweight | Get Alert |
| 06/21/2024 | Buy Now | 171.7% | Baird | Brian Skorney57% | $170 → $200 | Maintains | Outperform | Get Alert |
| 06/21/2024 | Buy Now | 189.36% | B of A Securities | Tazeen Ahmad56% | $166 → $213 | Maintains | Buy | Get Alert |
| 06/21/2024 | Buy Now | 219.25% | Needham | Gil Blum51% | $166 → $235 | Maintains | Buy | Get Alert |
| 06/18/2024 | Buy Now | 130.95% | BMO Capital | Kostas Biliouris34% | $170 → $170 | Maintains | Outperform | Get Alert |
| 06/14/2024 | Buy Now | 130.95% | BMO Capital | Kostas Biliouris34% | $170 → $170 | Maintains | Outperform | Get Alert |
| 05/31/2024 | Buy Now | 113.29% | Piper Sandler | Biren Amin40% | → $157 | Initiates | → Overweight | Get Alert |
| 05/28/2024 | Buy Now | 92.91% | RBC Capital | Brian Abrahams52% | $157 → $142 | Downgrade | Outperform → Sector Perform | Get Alert |
| 05/20/2024 | Buy Now | 125.51% | Needham | Gil Blum51% | $166 → $166 | Reiterates | Buy → Buy | Get Alert |
| 05/17/2024 | Buy Now | 143.17% | Mizuho | Uy Ear63% | $145 → $179 | Maintains | Buy | Get Alert |
| 05/14/2024 | Buy Now | 144.53% | Oppenheimer | Hartaj Singh47% | → $180 | Upgrade | Perform → Outperform | Get Alert |
| 05/03/2024 | Buy Now | 137.74% | JP Morgan | Anupam Rama60% | $177 → $175 | Maintains | Overweight | Get Alert |
| 05/02/2024 | Buy Now | 125.51% | Needham | Gil Blum51% | $166 → $166 | Reiterates | Buy → Buy | Get Alert |
| 05/02/2024 | Buy Now | 73.89% | Cantor Fitzgerald | Kristen Kluska70% | $128 → $128 | Reiterates | Neutral → Neutral | Get Alert |
| 03/01/2024 | Buy Now | 126.87% | UBS | Colin Bristow41% | $164 → $167 | Maintains | Buy | Get Alert |
| 02/29/2024 | Buy Now | 73.89% | Cantor Fitzgerald | Kristen Kluska70% | $128 → $128 | Reiterates | Neutral → Neutral | Get Alert |
| 02/29/2024 | Buy Now | 113.29% | RBC Capital | Brian Abrahams52% | $151 → $157 | Maintains | Outperform | Get Alert |
| 02/29/2024 | Buy Now | 133.66% | Citigroup | David Hoang42% | $160 → $172 | Maintains | Buy | Get Alert |
| 02/29/2024 | Buy Now | 151.32% | Barclays | Gena Wang51% | $141 → $185 | Maintains | Overweight | Get Alert |
| 02/29/2024 | Buy Now | 125.51% | Needham | Gil Blum51% | $169 → $166 | Maintains | Buy | Get Alert |
| 02/20/2024 | Buy Now | 204.31% | Wedbush | Andreas Argyrides69% | $224 → $224 | Reiterates | Outperform → Outperform | Get Alert |
| 02/20/2024 | Buy Now | 87.47% | Evercore ISI Group | Gavin Clark-Gartner41% | $108 → $138 | Maintains | In-Line | Get Alert |
| 02/16/2024 | Buy Now | 129.59% | Needham | Gil Blum51% | $140 → $169 | Maintains | Buy | Get Alert |
| 02/15/2024 | Buy Now | 73.89% | Cantor Fitzgerald | Kristen Kluska70% | $128 → $128 | Reiterates | Neutral → Neutral | Get Alert |
| 02/14/2024 | Buy Now | 73.89% | Cantor Fitzgerald | Kristen Kluska70% | $128 → $128 | Reiterates | Neutral → Neutral | Get Alert |
| 02/14/2024 | Buy Now | 96.98% | Mizuho | Uy Ear63% | $130 → $145 | Maintains | Buy | Get Alert |
| 01/31/2024 | Buy Now | 130.95% | BMO Capital | Kostas Biliouris34% | → $170 | Initiates | → Outperform | Get Alert |
| 01/30/2024 | Buy Now | 204.31% | Wedbush | Andreas Argyrides69% | $224 → $224 | Reiterates | Outperform → Outperform | Get Alert |
| 01/29/2024 | Buy Now | 90.19% | Needham | Gil Blum51% | $140 → $140 | Reiterates | Buy → Buy | Get Alert |
| 01/25/2024 | Buy Now | 105.14% | RBC Capital | Brian Abrahams52% | $155 → $151 | Maintains | Outperform | Get Alert |
| 01/10/2024 | Buy Now | 90.19% | Needham | Gil Blum51% | $93 → $140 | Maintains | Buy | Get Alert |
| 01/09/2024 | Buy Now | 204.31% | Wedbush | Andreas Argyrides69% | $224 → $224 | Reiterates | Outperform → Outperform | Get Alert |
| 12/13/2023 | Buy Now | 53.51% | Citigroup | David Hoang42% | → $113 | Initiates | → Buy | Get Alert |
| 12/12/2023 | Buy Now | 48.08% | Deutsche Bank | Neena Bitritto-Garg59% | → $109 | Initiates | → Buy | Get Alert |
| 11/21/2023 | Buy Now | 101.06% | RBC Capital | Brian Abrahams52% | → $148 | Reiterates | Outperform → Outperform | Get Alert |
| 11/21/2023 | Buy Now | 204.31% | Wedbush | Andreas Argyrides69% | → $224 | Initiates | → Outperform | Get Alert |
| 11/02/2023 | Buy Now | 91.55% | Barclays | Gena Wang51% | $193 → $141 | Maintains | Overweight | Get Alert |
| 11/02/2023 | Buy Now | 8.68% | Cantor Fitzgerald | Kristen Kluska70% | $40 → $80 | Maintains | Neutral | Get Alert |
| 11/02/2023 | Buy Now | 26.34% | Needham | Gil Blum51% | $82 → $93 | Maintains | Buy | Get Alert |
| 10/31/2023 | Buy Now | 56.23% | JP Morgan | Anupam Rama60% | $211 → $115 | Maintains | Overweight | Get Alert |
| 10/31/2023 | Buy Now | 101.06% | RBC Capital | Brian Abrahams52% | $217 → $148 | Maintains | Outperform | Get Alert |
| 10/31/2023 | Buy Now | -45.66% | Cantor Fitzgerald | Kristen Kluska70% | $166 → $40 | Downgrade | Overweight → Neutral | Get Alert |
| 10/31/2023 | Buy Now | 98.34% | Morgan Stanley | Matthew Harrison60% | $183 → $146 | Maintains | Overweight | Get Alert |
| 10/31/2023 | Buy Now | 11.4% | Needham | Gil Blum51% | $185 → $82 | Maintains | Buy | Get Alert |
| 09/26/2023 | Buy Now | 117.36% | Mizuho | Uy Ear63% | → $160 | Reiterates | Buy → Buy | Get Alert |
| 08/03/2023 | Buy Now | 151.32% | Needham | Gil Blum51% | → $185 | Reiterates | → Buy | Get Alert |
| 08/03/2023 | Buy Now | 148.61% | Morgan Stanley | Matthew Harrison60% | $183 → $183 | Reiterates | Overweight → Overweight | Get Alert |
| 08/03/2023 | Buy Now | 202.95% | RBC Capital | Brian Abrahams52% | $221 → $223 | Maintains | Outperform | Get Alert |
FAQ
What is the target price for Sarepta Therapeutics (SRPT) stock?
The latest price target for Sarepta Therapeutics (NASDAQ:SRPT) was reported by Scotiabank on March 20, 2025. The analyst firm set a price target for $80.00 expecting SRPT to rise to within 12 months (a possible 8.68% upside). 66 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Sarepta Therapeutics (SRPT)?
The latest analyst rating for Sarepta Therapeutics (NASDAQ:SRPT) was provided by Scotiabank, and Sarepta Therapeutics maintained their sector perform rating.
When was the last upgrade for Sarepta Therapeutics (SRPT)?
The last upgrade for Sarepta Therapeutics Inc happened on November 7, 2024 when Cantor Fitzgerald raised their price target to $167. Cantor Fitzgerald previously had a neutral for Sarepta Therapeutics Inc.
When was the last downgrade for Sarepta Therapeutics (SRPT)?
The last downgrade for Sarepta Therapeutics Inc happened on June 26, 2024 when Citigroup changed their price target from $172 to $176 for Sarepta Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Sarepta Therapeutics (SRPT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Sarepta Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Sarepta Therapeutics was filed on March 20, 2025 so you should expect the next rating to be made available sometime around March 20, 2026.
Is the Analyst Rating Sarepta Therapeutics (SRPT) correct?
While ratings are subjective and will change, the latest Sarepta Therapeutics (SRPT) rating was a maintained with a price target of $105.00 to $80.00. The current price Sarepta Therapeutics (SRPT) is trading at is $73.61, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.